| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Experimental Therapeutics |
The Prostate Centre, Vancouver General Hospital, Vancouver, British Columbia V6H 3Z6, [H. M., M. E. G.]; Department of Medical Oncology, British Columbia Cancer Agency, Vancouver, British Columbia, V5Z 4E6 [A. T.]; and Division of Urology, University of British Columbia, Vancouver, British Columbia V5Z 3J5 [M. E. G.], Canada
Progression to androgen-independence remains the main obstacle to improving survival for patients with advanced prostate cancer. Although Bcl-2 expression in normal prostatic epithelial cells is low or absent, Bcl-2 is highly up-regulated in prostate cancer cells after androgen withdrawal and during progression to androgen-independence. Here, we test the efficacy of antisense Bcl-2 oligodeoxynucleotide (ODN) therapy administered adjuvantly after castration to delay time to androgen-independent recurrence in the androgen-dependent mouse Shionogi tumor model. Treatment of Shionogi tumor cells in vitro with antisense Bcl-2 ODN inhibited Bcl-2 expression in a dose-dependent and sequence-specific manner. Systemic administration of antisense Bcl-2 ODN in mice bearing Shionogi tumors beginning 1 day postcastration resulted in a more rapid regression of tumors and a significant delay of emergence of androgen-independent recurrent tumors. Furthermore, despite significant reduction of Bcl-2 expression in tumor tissues, antisense Bcl-2 ODN had no effect on Bcl-2 expression in normal mouse organs. These findings illustrate the potential utility of antisense Bcl-2 therapy for prostate cancer in an adjuvant setting with androgen ablation.
This article has been cited by other articles:
|
|
 |
|
  J. Rom, G. von Minckwitz, F. Marme, B. Ataseven, D. Kozian, M. Sievert, B. Schlehe, F. Schuetz, A. Scharf, M. Kaufmann, et al. Phase I study of apoptosis gene modulation with oblimersen within preoperative chemotherapy in patients with primary breast cancer Ann. Onc., November 1, 2009; 20(11): 1829 - 1835. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Y. Khor, J. Moughan, T. Al-Saleem, E. H. Hammond, V. Venkatesan, S. A. Rosenthal, M. A. Ritter, H. M. Sandler, G. E. Hanks, W. U. Shipley, et al. Bcl-2 and Bax Expression Predict Prostate Cancer Outcome in Men Treated with Androgen Deprivation and Radiotherapy on Radiation Therapy Oncology Group Protocol 92-02 Clin. Cancer Res., June 15, 2007; 13(12): 3585 - 3590. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Benlloch, S. Mena, P. Ferrer, E. Obrador, M. Asensi, J. A. Pellicer, J. Carretero, A. Ortega, and J. M. Estrela Bcl-2 and Mn-SOD Antisense Oligodeoxynucleotides and a Glutamine-enriched Diet Facilitate Elimination of Highly Resistant B16 Melanoma Cells by Tumor Necrosis Factor-{alpha} and Chemotherapy J. Biol. Chem., January 6, 2006; 281(1): 69 - 79. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. So, S. Sinnemann, D. Huntsman, L. Fazli, and M. Gleave Knockdown of the cytoprotective chaperone, clusterin, chemosensitizes human breast cancer cells both in vitro and in vivo Mol. Cancer Ther., December 1, 2005; 4(12): 1837 - 1849. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Bartholomeusz, H. Itamochi, L. X.H. Yuan, F. J. Esteva, C. G. Wood, N. Terakawa, M.-C. Hung, and N. T. Ueno Bcl-2 Antisense Oligonucleotide Overcomes Resistance to E1A Gene Therapy in a Low HER2-Expressing Ovarian Cancer Xenograft Model Cancer Res., September 15, 2005; 65(18): 8406 - 8413. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Benlloch, A. Ortega, P. Ferrer, R. Segarra, E. Obrador, M. Asensi, J. Carretero, and J. M. Estrela Acceleration of Glutathione Efflux and Inhibition of {gamma}-Glutamyltranspeptidase Sensitize Metastatic B16 Melanoma Cells to Endothelium-induced Cytotoxicity J. Biol. Chem., February 25, 2005; 280(8): 6950 - 6959. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Yamanaka, M. E. Gleave, I. Hara, M. Muramaki, and H. Miyake Synergistic antitumor effect of combined use of adenoviral-mediated p53 gene transfer and antisense oligodeoxynucleotide targeting clusterin gene in an androgen-independent human prostate cancer model Mol. Cancer Ther., February 1, 2005; 4(2): 187 - 195. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. C. Lai, L. Benimetskaya, A. Khvorova, S. Wu, E. Hua, P. Miller, and C.A. Stein Phosphorothioate oligodeoxynucleotides and G3139 induce apoptosis in 518A2 melanoma cells Mol. Cancer Ther., February 1, 2005; 4(2): 305 - 315. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Biroccio and C. Leonetti Telomerase as a new target for the treatment of hormone-refractory prostate cancer Endocr. Relat. Cancer, September 1, 2004; 11(3): 407 - 421. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. V. July, E. Beraldi, A. So, L. Fazli, K. Evans, J. C. English, and M. E. Gleave Nucleotide-based therapies targeting clusterin chemosensitize human lung adenocarcinoma cells both in vitro and in vivo Mol. Cancer Ther., March 1, 2004; 3(3): 223 - 232. [Abstract] [Full Text]
|
|
|
|
|
|
A. Ortega, P. Ferrer, J. Carretero, E. Obrador, M. Asensi, J. A. Pellicer, and J. M. Estrela Down-regulation of Glutathione and Bcl-2 Synthesis in Mouse B16 Melanoma Cells Avoids Their Survival during Interaction with the Vascular Endothelium J. Biol. Chem., October 10, 2003; 278(41): 39591 - 39599. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Hu, G. Cherton-Horvat, V. Dragowska, S. Baird, R. G. Korneluk, J. P. Durkin, L. D. Mayer, and E. C. LaCasse Antisense Oligonucleotides Targeting XIAP Induce Apoptosis and Enhance Chemotherapeutic Activity against Human Lung Cancer Cells in Vitro and in Vivo Clin. Cancer Res., July 1, 2003; 9(7): 2826 - 2836. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. K. Cheema, S. K. Mishra, V. M. Rangnekar, A. M. Tari, R. Kumar, and G. Lopez-Berestein Par-4 Transcriptionally Regulates Bcl-2 through a WT1-binding Site on the bcl-2 Promoter J. Biol. Chem., May 23, 2003; 278(22): 19995 - 20005. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Zellweger, K. Chi, H. Miyake, H. Adomat, S. Kiyama, K. Skov, and M. E. Gleave Enhanced Radiation Sensitivity in Prostate Cancer by Inhibition of the Cell Survival Protein Clusterin Clin. Cancer Res., October 1, 2002; 8(10): 3276 - 3284. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. N. Chi, M. E. Gleave, R. Klasa, N. Murray, C. Bryce, D. E. Lopes de Menezes, S. D'Aloisio, and A. W. Tolcher A Phase I Dose-finding Study of Combined Treatment with an Antisense Bcl-2 Oligonucleotide (Genasense) and Mitoxantrone in Patients with Metastatic Hormone-refractory Prostate Cancer Clin. Cancer Res., December 1, 2001; 7(12): 3920 - 3927. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Miyake, I. Hara, S. Kamidono, and M. E. Gleave Synergistic Chemsensitization and Inhibition of Tumor Growth and Metastasis by the Antisense Oligodeoxynucleotide Targeting Clusterin Gene in a Human Bladder Cancer Model Clin. Cancer Res., December 1, 2001; 7(12): 4245 - 4252. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Zellweger, H. Miyake, S. Cooper, K. Chi, B. S. Conklin, B. P. Monia, and M. E. Gleave Antitumor Activity of Antisense Clusterin Oligonucleotides Is Improved in Vitro and in Vivo by Incorporation of 2'-O-(2-Methoxy)Ethyl Chemistry J. Pharmacol. Exp. Ther., September 1, 2001; 298(3): 934 - 940. [Abstract] [Full Text]
|
|
|
|
|
|
T. Nickerson, F. Chang, D. Lorimer, S. P. Smeekens, C. L. Sawyers, and M. Pollak In Vivo Progression of LAPC-9 and LNCaP Prostate Cancer Models to Androgen Independence Is Associated with Increased Expression of Insulin-like Growth Factor I (IGF-I) and IGF-I Receptor (IGF-IR) Cancer Res., August 1, 2001; 61(16): 6276 - 6280. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. W. Tolcher Novel Compounds in the Therapy of Breast Cancer: Opportunities for Integration with Docetaxel Oncologist, June 1, 2001; 6(2008): 40 - 44. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. R. Smith, T. Xie, Z.-Z. Zhou, and I. Joshi Efficacy of Treatment with Antisense Oligonucleotides Complementary to Immunoglobulin Sequences of bcl-2/Immunoglobulin Fusion Transcript in a t(14;18) Human Lymphoma-scid Mouse Model Clin. Cancer Res., February 1, 2001; 7(2): 400 - 406. [Abstract] [Full Text]
|
|
|
|
 |
|
 C. Abate-Shen and M. M. Shen Molecular genetics of prostate cancer Genes & Dev., October 1, 2000; 14(19): 2410 - 2434. [Full Text]
|
|
|
|
|
|
D. E. Lopes de Menezes, N. Hudon, N. McIntosh, and L. D. Mayer Molecular and Pharmacokinetic Properties Associated with the Therapeutics of Bcl-2 Antisense Oligonucleotide G3139 Combined with Free and Liposomal Doxorubicin Clin. Cancer Res., July 1, 2000; 6(7): 2891 - 2902. [Abstract] [Full Text]
|
|
|
|
 |
|
 H. Miyake, C. Nelson, P. S. Rennie, and M. E. Gleave Overexpression of Insulin-Like Growth Factor Binding Protein-5 Helps Accelerate Progression to Androgen-Independence in the Human Prostate LNCaP Tumor Model through Activation of Phosphatidylinositol 3'-Kinase Pathway Endocrinology, June 1, 2000; 141(6): 2257 - 2265. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Miyake, M. Pollak, and M. E. Gleave Castration-induced Up-Regulation of Insulin-like Growth Factor Binding Protein-5 Potentiates Insulin-like Growth Factor-I Activity and Accelerates Progression to Androgen Independence in Prostate Cancer Models Cancer Res., June 1, 2000; 60(11): 3058 - 3064. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. N. Sumantran, D. S. Lee, V. V. Baker, S. Murray, M. Strawderman, and M. S. Wicha A Bcl-xS Adenovirus Demonstrates Therapeutic Efficacy in an Ascites Model of Human Breast Cancer Reproductive Sciences, May 1, 2000; 7(3): 184 - 189. [Abstract] [PDF]
|
|
|
|
|
|
H. Miyake, C. Nelson, P. S. Rennie, and M. E. Gleave Acquisition of Chemoresistant Phenotype by Overexpression of the Antiapoptotic Gene Testosterone-repressed Prostate Message-2 in Prostate Cancer Xenograft Models Cancer Res., May 1, 2000; 60(9): 2547 - 2554. [Abstract] [Full Text]
|
|
|
|
|
|
H. Miyake, K. N. Chi, and M. E. Gleave Antisense TRPM-2 Oligodeoxynucleotides Chemosensitize Human Androgen-independent PC-3 Prostate Cancer Cells Both in Vitro and in Vivo Clin. Cancer Res., May 1, 2000; 6(5): 1655 - 1663. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Miayake, A. Tolcher, and M. E. Gleave Chemosensitization and Delayed Androgen-Independent Recurrence of Prostate Cancer With the Use of Antisense Bcl-2 Oligodeoxynucleotides J Natl Cancer Inst, January 5, 2000; 92(1): 34 - 41. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Miyake, C. Nelson, P. S. Rennie, and M. E. Gleave Testosterone-repressed Prostate Message-2 Is an Antiapoptotic Gene Involved in Progression to Androgen Independence in Prostate Cancer Cancer Res., January 1, 2000; 60(1): 170 - 176. [Abstract] [Full Text]
|
|
|
|
|
|
M. Gleave, A. Tolcher, H. Miyake, C. Nelson, B. Brown, E. Beraldi, and J. Goldie Progression to Androgen Independence Is Delayed by Adjuvant Treatment with Antisense Bcl-2 Oligodeoxynucleotides after Castration in the LNCaP Prostate Tumor Model Clin. Cancer Res., October 1, 1999; 5(10): 2891 - 2898. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
